Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.
J Pediatr Hematol Oncol
; 41(7): e481-e483, 2019 10.
Article
em En
| MEDLINE
| ID: mdl-30045148
ABSTRACT
We describe a patient with Down syndrome whose precursor B-cell acute lymphoblastic leukemia cells expressed INPP5D-ABL1 fusion gene that resulted in a reciprocal chromosome translocation t(2;9)(q27;q34). The fusion gene was present as a small subclone in the primary disease but was first identified at relapse when the subclone had expanded into a major clone. At relapse, the patient responded poorly to conventional induction chemotherapy but a transient morphologic remission was achieved after administration of imatinib monotherapy. This case demonstrates a pathway to relapse in a Down syndrome patients with acute lymphoblastic leukemia through a rare fusion event. It highlights the significance of minor subclonal events in therapy resistance and the opportunity provided for targeted therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia-Linfoma Linfoblástico de Células Precursoras B
/
Proteínas Proto-Oncogênicas c-abl
/
Mesilato de Imatinib
/
Fosfatidilinositol-3,4,5-Trifosfato 5-Fosfatases
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Adolescent
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article